SCHEMBL593286

SCHEMBL593286

CC(C)OC(=O)CCCN

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.61
CYP1A2 P05177 2/20 0.54
TSHR P16473 4/20 0.42
GABRR3 A8MPY1 1/20 0.42
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
HDAC3 O15379 1/20 0.42
GABBR2 O75899 1/20 0.42
THRB P10828 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRR1 P24046 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRR2 P28476 1/20 0.42
SLC6A1 P30531 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
GABRB2 P47870 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10347010 0.98 LMNA (0.59) LMNACYP1A2TSHRGABRR3GABRP
SCHEMBL28864170 0.93 LMNA (0.64) LMNACYP1A2TSHRTHRBBLM
SCHEMBL11266298 0.91 LMNA (0.68) LMNACYP1A2THRBBLMKMT2A
SCHEMBL18476686 0.91 LMNA (0.68) LMNACYP1A2THRBBLMKMT2A
Ethylenediamine SCHEMBL7702427 0.86 LMNA (0.54) LMNACYP1A2TSHRGABRR1MAPT
SCHEMBL7078022 0.86
SCHEMBL15391 0.85 LMNA (0.78) LMNACYP1A2TSHRMAPTALOX15
SCHEMBL8104259 0.85 LMNA (0.78) LMNACYP1A2TSHRMAPTALOX15
SCHEMBL18619 0.85 LMNA (0.71) LMNATSHRMAPTALOX15CASP1
SCHEMBL31245871 0.85 LMNA (0.50) LMNACYP1A2TSHRMAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109251163-A A kind of method for splitting of indoline -2- formic acid compound and wherein mesosome 江苏永达药业有限公司 2019-01-22 CN claimed
EP-1603549-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS Yu, Ruey J., Dr. (US) 2005-12-14 EP claimed
WO-2004082628-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS YU RUEY J (US) 2004-09-30 WO claimed
CN-114901646-B Benzotriazine bisoxides and pharmaceutical compositions thereof 浙江瑞臻医药有限公司 2024-06-04 CN disclosed
US-20230321228-A1 VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME EUAGORE, LLC 2023-10-12 US disclosed
WO-2023019912-A9 BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF 杭州瑞臻医药有限公司 2023-06-01 WO disclosed
WO-2023019912-A1 BENZOTRIAZINE DIOXIDE AND PHARMACEUTICAL COMPOSITION THEREOF 杭州瑞臻医药有限公司 2023-02-23 WO disclosed
WO-2023000708-A1 POLYSUBSTITUTED PURINE COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国药科大学 2023-01-26 WO disclosed
CN-114901646-A Benzotriazine double oxide and pharmaceutical composition thereof 杭州瑞臻医药有限公司 2022-08-12 CN disclosed
US-10829454-B2 Compositions and methods for the treatment of Parkinson's disease CELLIX BIO PRIVATE LIMITED (IN) 2020-11-10 US disclosed
CN-110938095-A Novel tenofovir mixed ester-amide prodrug 正大天晴药业集团股份有限公司 2020-03-31 CN disclosed
WO-2008049806-A1 PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-05-02 WO disclosed
WO-2008049806-A1 PIPERIDINE OR PIPERAZINE SUBSTITUTED TETRAHYDRO-NAPHTHALENE-1-CARBOXYLIC ACID MTP INHIBITING COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-05-02 WO disclosed
EP-1613597-B1 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2007-11-07 EP disclosed
EP-1603549-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS Yu, Ruey J., Dr. (US) 2005-12-14 EP disclosed
US-20040220264-A1 Bioavailability and improved delivery of acidic pharmaceutical drugs YU RUEY J 2004-11-04 US disclosed
WO-2004082628-A2 IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ACIDIC PHARMACEUTICAL DRUGS YU RUEY J (US) 2004-09-30 WO disclosed
CN-1053472-C Oligonucleotides derived from the SOD family HOFFMANN LA ROCHE (CH) 2000-06-14 CN disclosed
US-5618814-A Trisubstituted pyrimido [5,4-d] pyrimidines for modulating multi-drug resistance and pharmaceutical compositions containing these compounds DR. KARL THOMAE GMBH (DE) 1997-04-08 US disclosed
CN-1106405-A Trisubstituted pyrimido [5,4-d] pyrimidines for modulating THOMAE GMBH DR K (DE) 1995-08-09 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10829454-B2 Compositions and methods for the treatment of Parkinson's disease PARK7, SNCA, SLC6A3 LMNA 1211/4885CYP1A2 627/4885TSHR 2918/4885
US-20230321228-A1 VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME MYD88, TLR9, TLR5 LMNA 3387/4885CYP1A2 3945/4885TSHR 4380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.